Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H24N2O4.ClH |
Molecular Weight | 380.866 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C(OCC(O)CNCCOC2=CC=C(C=C2)C(N)=O)C=CC=C1
InChI
InChIKey=ZATQSCRQPQXBEG-UHFFFAOYSA-N
InChI=1S/C19H24N2O4.ClH/c1-14-4-2-3-5-18(14)25-13-16(22)12-21-10-11-24-17-8-6-15(7-9-17)19(20)23;/h2-9,16,21-22H,10-13H2,1H3,(H2,20,23);1H
Tolamolol is a phenoxypropranolamine derivative that preferentially inhibits myocardial beta adrenoreceptors, possesses beta blocking potency equivalent to propranolol, has little or no direct cell membrane effect and lacks beta adrenergic stimulating action. Cardioselective beta adrenergic blockade with tolamolol was highly effective in controlling ventricular rate in supraventricular arrhythmias and reduced the frequency of ventricular ectopic beats in half of the small group of patients with this arrhythmia. It is particularly applicable in patients with obstructive pulmonary disease in whom cardiac beta adrenergic blockade is indicated. Hypotension is an important potential side effect. Tolamolol and propranolol are equal in anti-anginal efficacy but tolamolol has the advantage of being cardioselective. It is superior to practolol. Tolamolol had no effect on sperm motility.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of beta-adrenoceptor blocking drugs, physostigmine, and atropine on the toxicity of doxepin in mice. | 1975 Aug |
|
Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris. | 1975 Mar 29 |
|
Efficacy of cardioselective beta adrenergic blockade with intravenously administered tolamolol in the treatment of cardiac arrhythmias. | 1976 Aug |
|
Antihypertensive action of drug combination: polythiazide, prazosin and tolamolol. | 1977 Feb |
|
Beta-adrenergic blockade of the lung. Dose-dependent cardioselectivity of tolamolol in asthma. | 1978 Jun |
|
Tolamolol, a beta adrenergic blocking agent: study of its efficacy in angina pectoris. | 1978 Sep |
|
Beta-adrenoceptor antagonists and human sperm motility. | 1990 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/804952
200 mg thrice daily for a month
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
170731
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
PRIMARY | |||
|
43064-17-1
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
SUPERSEDED | |||
|
51599-37-2
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
PRIMARY | |||
|
100000084653
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
PRIMARY | |||
|
SUB04905MIG
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
PRIMARY | |||
|
25619NA95Y
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
PRIMARY | |||
|
DTXSID00962876
Created by
admin on Sat Dec 16 10:44:09 GMT 2023 , Edited by admin on Sat Dec 16 10:44:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD